Dr. Junjie Peng 彭俊杰
Chief Physician
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Multidisciplinary treatment of colorectal cancer, including radical surgery for locally advanced cases, reoperation for local recurrence, and management of liver metastases. Expertise in minimally invasive surgery, sphincter-preserving procedures for low rectal cancer, and colorectal neuroendocrine tumors.
Dr. Peng is Director of the Comprehensive Colorectal Treatment Department at Fudan University Shanghai Cancer Center, where they have worked since 2006. They hold a PhD in Oncology from Fudan University and completed a clinical postdoctoral fellowship at the UCSF Helen Diller Family Comprehensive Cancer Center. Research focuses on multidisciplinary rectal cancer care, recurrent and metastatic disease, and neuroendocrine tumors. Dr. Peng has authored over 50 SCI papers.
Professional roles
- Youth Committee Member, Colorectal Cancer Professional Committee, China Anti-Cancer Association
- Member, Liver Metastasis Group, China Anti-Cancer Association
- Member, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Peng Junjie). Papers usually list the name as Junjie Peng or Peng J.
Selected publications
96 papers on PubMed matched by name and affiliation; 32 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Clin Oncol, 2026 (senior author): Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Nonmetastatic Colorectal Cancer: A Prospective, Randomized, Phase III FIND Trial. PubMed 42525894
- Eur J Cancer, 2026 (senior author): Circulating tumor DNA-guided therapeutic strategies for metastatic colorectal cancer patients with multiple small pulmonary-limited nodules: A prospective cohort study. PubMed 42962410
- Drug Resist Updat, 2026 (senior author): Functional precision oncology platform of BRAF(V600E)-mutated colorectal cancer organoids predicts therapy response and reveals RNF43-mediated immunogenicity. PubMed 42190325
- MedComm (2020), 2026 (senior author): Tumor Organoid and Microenvironment Cocultures: Implications for Basic and Translational Cancer Research. PubMed 41987851
- JMIR Form Res, 2025 (senior author): A Machine Learning-Based Scoring System to Identify High Immunoactivity Microsatellite Stability Tumors by Quantifying Similarity to Microsatellite Instability-High Tumors in Colorectal Cancers: Development and Quantitative Study. PubMed 41100766
- J Gastrointest Oncol, 2025 (senior author): Survival of hepatectomy in colorectal cancer patients with ten or more liver metastases: a retrospective cohort study of multidisciplinary treatment. PubMed 40950338
- Int J Surg, 2024 (senior author): Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study. PubMed 38445460
- Heliyon, 2024 (senior author): Association of preoperative and recurrent serum carcinoembryonic antigen and outcome of colorectal cancer patients with metastatic relapse. PubMed 38617920
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion